Cutaneous adverse‐events in patients treated with Ibrutinib
Alessandro Pileri, Alba Guglielmo, Claudio Agostinelli, Valeria Evangelista, Clara Bertuzzi, Aurora Alessandrini, Francesca Bruni, Michela Starace, A Massi, Alessandro Broccoli, Annalisa Patrizi, Pier Luigi Zinzani, Bianca Maria Piraccini
Abstract
Ibrutinib is a Burton tyrosine kinase inhibitor (BTKi) approved for the treatment of several hematologic malignancies. Analyze skin adverse events (SAE). All the patients treated with Ibrutinib featuring cutaneous adverse events were selected. Twenty five patients were retrieved with a median interval between Ibrutinib start and SAE time of onset of 120 days. Most common SAE observed involved hairs and nails. Eczematous reaction and leucocytoclastic vasculitis were also detected. One patient had a long-history Ibrutinib treatment and experienced numerous cutaneous adverse events. Infective disease such as superficial mycosis and impetigo were rarely present in our series. Despite the development of cutaneous SAE, all the patients continued their concomitant drugs without the onset of any further SAE. Our data suggest Ibrutinib-associated rash should be distinguished in early and late events and a careful dermatologic management of patients should be scheduled.